Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Hepatology

• Publication date

  2013-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.26585PMID 23787814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma

  2013cited by this paper
• Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

  2013cited by this paper
• Differential secretome analysis of cancer‐associated fibroblasts and bone marrow‐derived precursors to identify microenvironmental regulators of colon cancer progression

  2013cited by this paper
• Functional Screen of Paracrine Signals in Breast Carcinoma Fibroblasts

  2012cited by this paper
• Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma.

  2012cited by this paper
• Clinicopathological significance of E-cadherin, β-catenin and epidermal growth factor receptor expression in intrahepatic cholangiocarcinoma.

  2012cited by this paper
• Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

  2012cited by this paper
• Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells

  2012cited by this paper
• The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma

  2012cited by this paper
• Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

  2012cited by this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012influential reference
• Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma.

  2012cited by this paper
• Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling

  2012cited by this paper
• Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

  2011cited by this paper
• Myofibroblast‐derived PDGF‐BB promotes hedgehog survival signaling in cholangiocarcinoma cells

  2011cited by this paper
• Tangled fibroblasts in tumor‐stroma interactions

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers.

  2011cited by this paper
• Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells.

  2010cited by this paper
• Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

  2010cited by this paper
• Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma

  2009cited by this paper
• Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma.

  2009cited by this paper
• Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway

  2008cited by this paper
• Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy.

  2008cited by this paper
• Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

  2008influential reference
• Stromal myofibroblasts are drivers of invasive cancer growth

  2008cited by this paper
• HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.

  2008cited by this paper
• Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition

  2008cited by this paper
• EGFR and HER2 expression in advanced biliary tract cancer.

  2008cited by this paper
• Validation of HB-EGF and amphiregulin as targets for human cancer therapy.

  2008cited by this paper
• Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front

  2008cited by this paper
• Transforming growth factor-beta and fibrosis.

  2007cited by this paper
• Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

  2007influential reference
• Transforming growth factor-β and fibrosis

  2007cited by this paper
• Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy

  2006cited by this paper
• Phase II study of erlotinib in patients with advanced biliary cancer.

  2006cited by this paper
• Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

  2006cited by this paper
• Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma

  2006cited by this paper
• The complexity of targeting EGFR signalling in cancer: from expression to turnover.

  2006cited by this paper
• Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: Comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas

  2005cited by this paper
• Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

  2005cited by this paper
• Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells

  2004cited by this paper
• Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.

  2004influential reference
• Quantification of human Alu sequences by real-time PCR – an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants

  2004cited by this paper
• Transforming Growth Factor β1 Stimulates Vascular Endothelial Growth Factor Gene Transcription in Human Cholangiocellular Carcinoma Cells

  2003cited by this paper
• Abnormal distribution of collagen type IV in extrahepatic bile duct carcinoma

  2000cited by this paper
• Expression of heregulin α, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells

  1999cited by this paper
• Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.

  1999cited by this paper
• Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas.

  1996cited by this paper
• Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas.

  1996cited by this paper
• Transforming growth factor beta 1 in human liver tumors.

  1995cited by this paper

• Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity

  2026cites this paper
• Cancer-associated fibroblast-derived extracellular vesicles regulate lipophagy through PLIN2 to modulate dormancy in salivary gland adenoid cystic carcinoma cells

  2025cites this paper
• Cancer-associated fibroblasts in cholangiocarcinoma: the central nexus of tumor-stroma crosstalk and therapeutic translation

  2025cites this paper
• Metastatic microenvironment of extrahepatic cholangiocarcinoma.

  2025cites this paper
• Activated cancer-associated fibroblasts correlate with poor survival and decreased lymphocyte infiltration in infiltrative type distal cholangiocarcinoma

  2025cites this paper
• The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies

  2025cites this paper
• Prediction of CAF-related genes in immunotherapy and drug sensitivity in hepatocellular carcinoma: a multi-database analysis

  2024cites this paper
• The role of mesenchymal cells in cholangiocarcinoma

  2024cites this paper
• Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications

  2024cites this paper
• Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma: Insights into Origins, Heterogeneity, Lymphangiogenesis, and Peritoneal Metastasis.

  2024cites this paper
• Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression

  2024cites this paper
• The role of extracellular vesicles in cholangiocarcinoma tumor microenvironment

  2024cites this paper
• Cholangiokines: undervalued modulators in the hepatic microenvironment

  2023cites this paper
• Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)

  2023cites this paper
• Cartilage oligomeric matrix protein overexpression is an independent poor prognostic indicator in patients with intrahepatic cholangiocarcinoma

  2023cites this paper
• NOTCH signalling – a core regulator of bile duct disease?

  2023cites this paper
• Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components

  2023cites this paper
• The Origin, Differentiation, and Functions of Cancer-Associated Fibroblasts in Gastrointestinal Cancer

  2023cites this paper
• Fibroblasts in liver cancer: functions and therapeutic translation.

  2023cites this paper
• Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.

  2023cites this paper
• MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway.

  2023cites this paper
• Heterogeneity of Cholangiocarcinoma Immune Biology

  2023cites this paper
• Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective

  2023cites this paper
• Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma

  2023cites this paper
• Matricellular proteins in intrahepatic cholangiocarcinoma.

  2022cites this paper
• Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition

  2022cites this paper
• Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy

  2022cites this paper
• Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine

  2022cites this paper
• Advances of cancer-associated fibroblasts in liver cancer

  2022cites this paper
• Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.

  2022cites this paper
• Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma

  2022cites this paper
• Insights into the role of STAT3 in intrahepatic cholangiocarcinoma

  2022cites this paper
• EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription

  2022cites this paper
• Zinc Finger E‐Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor–Stroma Paracrine Signaling

  2021cites this paper
• Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

  2021cites this paper
• Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma

  2021cites this paper
• CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase

  2021cites this paper
• The Tumor Environment: Cholangiocarcinoma-Associated Fibroblasts and Beyond

  2021cites this paper
• Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro.

  2021cites this paper
• Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells

  2020cites this paper
• Cancer-associated fibroblasts in cholangiocarcinoma.

  2020cites this paper
• Tumor Microenvironment: Non-Hematopoietic Cells

  2020cites this paper
• Hepatic Stellate Cells in Liver Tumor.

  2020cites this paper
• The Tumor Microenvironment in Cholangiocarcinoma Progression

  2020cites this paper
• Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis

  2020cites this paper
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management

  2020influential citation
• ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

  2020cites this paper
• Role of Chemokines in the Biology of Cholangiocarcinoma

  2020cites this paper
• Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.

  2020cites this paper
• Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance

  2020cites this paper
• Neuropilin‐1 is up‐regulated by cancer‐associated fibroblast‐secreted IL‐8 and associated with cell proliferation of gallbladder cancer

  2020cites this paper
• FAP‐Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer Associated Fibroblasts

  2020cites this paper
• Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy

  2020cites this paper
• World Journal of Gastroenterology Treatment for inflammatory using literature-related discovery and in primary liver tumors: A challenging role of natural killer cells

  2020cites this paper
• Chemokines in the cholangiocarcinoma

  2020cites this paper
• Cancer-associated fibroblasts in gastrointestinal cancer

  2019cites this paper
• MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment

  2019cites this paper
• Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

  2019cites this paper
• Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms

  2019cites this paper
• Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications

  2019cites this paper
• Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor

  2019cites this paper
• The tumour microenvironment and immune milieu of cholangiocarcinoma

  2019cites this paper
• Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

  2019cites this paper
• Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment

  2019cites this paper
• The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium

  2018cites this paper
• Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology

  2018cites this paper
• Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells.

  2018cites this paper
• Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma.

  2018cites this paper
• Isolation of cancer‐associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma

  2018cites this paper
• Precision medicine in cholangiocarcinoma.

  2018cites this paper
• Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma

  2017cites this paper
• Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

  2017influential citation
• The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.

  2017cites this paper
• Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma

  2017cites this paper
• Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor.

  2017cites this paper
• Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

  2017cites this paper
• Cholangiocarcinoma.

  2017cites this paper
• Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness

  2017cites this paper
• Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy.

  2017cites this paper
• Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma

  2017cites this paper
• The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

  2017cites this paper
• Biology of Disease and Prognostic Factors of Cholangiocarcinomas

  2017cites this paper
• Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

  2017cites this paper
• Tumor Stroma, Desmoplasia, and Stromagenesis

  2016cites this paper
• Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

  2016cites this paper
• Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease.

  2016cites this paper
• Hepatitis B virus X induces inflammation and cancer in mice liver through dysregulation of cytoskeletal remodeling and lipid metabolism

  2016cites this paper
• E-cadherin, guardian of liver physiology.

  2015cites this paper
• Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures

  2015cites this paper
• EGFR Signaling in Liver Diseases

  2015cites this paper
• Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.

  2014cites this paper
• Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities

  2014cites this paper
• EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.

  2014cites this paper
• Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma.

  2014cites this paper
• Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting

  2014cites this paper
• Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.

  2013cites this paper
• Edinburgh Research Explorer Expert consensus document

  year unknowncites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper